Ischemix, Inc. is a clinical-stage company developing novel cytoprotective compounds to prevent and treat serious diseases or conditions. The company’s lead product candidate, CMX-2043, is a chemically-modified form of a naturally-occurring compound, with increased potency and comparable safety relative to the native molecule. The Company is conducting a 340-patient Phase 2a trial of CMX-2043 for prevention of acute kidney injury due to contrast media exposure (CI-AKI); full data from the trial is expected early-2016. In a previously completed 142-patient Phase 2a trial in PCI patients, CMX-2043 demonstrated statistical significance in the reduction of biomarkers of cardiac injury. Ischemix is also conducting pre-clinical studies of its compounds in the treatment of traumatic brain injury.
Ischemix (pronounced iss-KEY-mix) is based on the word “ischemia” which describes the medical condition of insufficient blood flow to living cells or organs of the body. The word has a Greek origin; isch means restriction, hema or haema refers to blood.
Contrast Induced Acute Kidney Injury
Contrast induced acute kidney injury is a known risk from the use of contrast agents in diagnostic radiology procedures and is one of the leading causes of hospital-acquired acute renal failure. It is associated with a significantly increased risk of in-hospital and 1-year mortality.
In the general population, the risk of acquiring AKI/CIN is relatively low. However, this risk can be substantially higher in some patients, especially those
undergoing cardiac procedures.
A heart attack or “myocardial infarction” is usually caused by blockage of an artery supplying the heart. Muscle cells beyond the block are then deprived of oxygen and nutrients. This ischemic event leads to regional cell death which may be fatal.
Cardiac surgeries and interventional procedures to restore or improve blood flow may temporarily increase ischemia, and also paradoxically result in additional “reperfusion injury” caused by the rapid restoration of blood flow. Ischemia-reperfusion injury can exceed the initial ischemic damage. Ischemia-reperfusion injury can lead to extended hospital stay, limit recovery in patients undergoing cardiac surgeries and interventional procedures, and add to hospital costs.